Mike Diem, MD, MBA

Michael Diem is Chief Business Officer at Century Therapeutics. Before joining Century, Mike was Senior Vice President of Business and Corporate Development at Amicus Therapeutics and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier in his career, he was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca, where he was responsible for mergers and acquisitions, divestitures, and managed the company’s strategic investment activities and MedImmune Ventures. At GlaxoSmithKline, he led business development for the company’s rare disease business unit. He was also a partner in GSK’s corporate venture firm, SR One, Limited.

Mike holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School, and an MBA from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow. He currently serves as a board director at VenatoRx Pharmaceuticals and the Boys and Girls Clubs of Philadelphia.